Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

regulatory

- PMLiVE

ISPOR’s 2026–2027 HEOR Trends report: The Era of Evidence Judgment

In response to ISPOR’s recently published 2026-2027 HEOR Trends, David Miller, CEO, Genesis Research Group, suggests that we’re no longer being evaluated on our ability to produce data, but on...

Genesis Research Group

- PMLiVE

Uncovering Inequities in Alzheimer’s Disease Screening and Care

  On December 5, MAPS hosted an educational webinar exploring recent research in Alzheimer’s disease (AD) screening, testing, and treatment. Experts from Komodo Health and Medscape shared findings from their...

Medscape Education

Headshot of Sarah Theobald with text reading 'Healthcare communications trends in 2026'

What will healthcare communications look like in 2026? Amiculum’s prediction of upcoming trends

By Sarah Theobald

Amiculum

Quote from the article: Without adapting JCA to include assessment of real-world data and broader benefits, vaccines may be undervalued

Is Joint Clinical Assessment (JCA) appropriate for assessing the broader value of vaccines?

By Emily Morton-West

Amiculum

- PMLiVE

Lilly announces plan for new $3bn facility to boost manufacturing in Europe

The facility will be built in the Netherlands and will increase capacity for the company's oral medicines portfolio

- PMLiVE

EU medicine shortages hit record highs in 2023 and 2024

Even with countermeasures in place, European auditors warn that the risks remain elevated

ECA webinar image

ISPOR hosts expert webinar exploring the value of ECAs for regulatory and HTA evidence needs

On Tuesday, October 7th, you are invited to join a Genesis Research Group-led webinar exploring the value of External Control Arm (ECA) studies. Gaining traction as part of evidence generation...

Genesis Research Group

Dave Miller on Biotechs image

Dave W. Miller interviewed by Paige McGarry on the unique challenges faced by biotech companies

HealthEconomics.com interviews David W. Miller, CEO of Genesis Research Group, to discuss the unique challenges faced by biotech companies in evidence generation, market access, and stakeholder engagement.

Genesis Research Group

- PMLiVE

Insights From ISPOR 2025: R In Health Technology Assessment – Is It The Future?

ISPOR’s annual meeting in Montreal this May was packed with opportunities to explore the latest trends, insights, and research in HEOR and market access. In this series, our experts share...

Petauri Evidence

ISPOR partner seal

Genesis Research Group announces inaugural membership of ISPOR Corporate Partnership Program

Genesis Research Group, a pioneer of tech-enabled real-world evidence (RWE), health economics and outcomes research (HEOR), and market access services, today announces it has joined selected organizations as an inaugural...

Genesis Research Group

- PMLiVE

Your essential guide to the World EPA Congress 2025: Top sessions and pre-reading

The World EPA organisers have curated an exceptional programme featuring thought-provoking presentations and dynamic panel sessions led by industry leaders driving market access strategy and practice. Following the opening keynote...

Petauri Evidence

- PMLiVE

What does HEOR really mean in 2025?

Global healthcare systems are under unprecedented strain. As life expectancies rise and populations age, the proportion of people aged 60+ years is expected to soar. This both signals remarkable progress...

Petauri Evidence

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links